John McGrath, Chief Financial Officer at Atara Biotherapeutics, Inc. (ATRA), sold 6,000 shares at $49.38 ($296K) on 2015-08-18, disclosed to the SEC on 2015-08-19.
Scheduled sale ($296k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| ATRA | SELL | 2018-01-12 | $901K | — | Filing → |
| ATRA | SELL | 2018-01-02 | $640K | — | Filing → |
| ATRA | SELL | 2017-08-17 | $60K | — | Filing → |